Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 9/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145273 | 0.95 | ALDH1A1 (0.49) | POLBCA12CA9CCR2DRD4 | |
| SCHEMBL3139557 | 0.89 | DRD4 (0.48) | DRD4 | |
| SCHEMBL3153187 | 0.89 | CA12 (0.50) | CA12CA9CCR2CACNA1GLMNA | |
| SCHEMBL3157190 | 0.88 | CCR2 (0.52) | POLBCA12CA9CCR2DRD4 | |
| SCHEMBL3149321 | 0.86 | KMT2A (0.47) | LMNA | |
| SCHEMBL3148182 | 0.85 | F10 (0.51) | CA12CA9CCR2DRD4F10 | |
| SCHEMBL3153773 | 0.84 | ALDH1A1 (0.45) | CA12CA9CCR2DRD4F10 | |
| SCHEMBL3140709 | 0.84 | NAMPT (0.47) | CA12CA9CCR2DRD4F10 | |
| SCHEMBL3149360 | 0.84 | CA12 (0.59) | POLBCA12CA9CACNA1GMCHR1 | |
| SCHEMBL3149168 | 0.83 | F10 (0.53) | CA12CA9CCR2DRD4F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | POLB 3939/4885CA12 2341/4885CA9 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.